问鼎娱乐.com|极速飞艇的冠亚和计划|极速赛车计划群群名|sg幸运飞艇计划官方版下载

<label id="6kt4j"></label>

    <li id="6kt4j"></li>
        1. Nature Chemical Biology| 翌圣轉(zhuǎn)染試劑助力大麻素受體CB1的變構(gòu)調(diào)節(jié)機(jī)制研究

          大麻素受體CB1是人類中樞神經(jīng)系統(tǒng)表達(dá)量最高的G蛋白偶聯(lián)受體(GPCR)之一,主要位于腦、脊髓與外周神經(jīng)系統(tǒng)中,參與調(diào)節(jié)人體的新陳代謝、食欲、疼痛、記憶和學(xué)習(xí)、神經(jīng)系統(tǒng)和心血管系統(tǒng)等生理過程。其配體(包括激動劑和拮抗劑)可用于治療疼痛、炎癥、神經(jīng)退行性疾病、肥胖、藥物成癮以及肝纖維化等。靶向CB1的藥物開發(fā)備受關(guān)注,眾多藥企與科研團(tuán)隊(duì)都聚焦于該受體的藥物研發(fā)。但CB1變構(gòu)調(diào)節(jié)的具體分子機(jī)制尚不清楚,嚴(yán)重阻礙了變構(gòu)藥物的研發(fā)。

          1655608379955841.png

           

          2022年5月30日,四川大學(xué)華西醫(yī)院生物治療國家重點(diǎn)實(shí)驗(yàn)室楊勝勇教授團(tuán)隊(duì)聯(lián)合生物治療國家重點(diǎn)實(shí)驗(yàn)室/腎臟內(nèi)科邵振華研究員團(tuán)隊(duì)《Nature Chemical Biology》期刊(IF:15.04)在線發(fā)表了題為《Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1》的研究論文。充分運(yùn)用計(jì)算機(jī)輔助藥物設(shè)計(jì)的多種技術(shù)方法對大麻素受體CB1分別與正向變構(gòu)調(diào)節(jié)劑ZCZ011及負(fù)向別構(gòu)調(diào)節(jié)劑ORG27569的相互作用機(jī)理進(jìn)行研究,讓我們對CB1受體別構(gòu)調(diào)節(jié)的分子機(jī)理有了更充分的理解,為設(shè)計(jì)與篩選更合適的藥物提供了重要的理論依據(jù)。

           

          1655608448999440.png

           

          在該研究中,研究團(tuán)隊(duì)選擇了翌圣的轉(zhuǎn)染試劑PEI40000用于相關(guān)蛋白的研究:

           

          3.png

           

           

          目前轉(zhuǎn)染試劑系列的產(chǎn)品已經(jīng)榮登《Nature》、《Cell》等多個頂級期刊,獲得科研大牛們認(rèn)可!

          IF55分!翌圣轉(zhuǎn)染試劑助力高分文章

          翌圣明星CP--轉(zhuǎn)染試劑與PCR產(chǎn)品又登《Cell》期刊

          超燃!翌圣轉(zhuǎn)染試劑助力這個團(tuán)隊(duì)連發(fā)3篇IF10+文章

           

          以下僅展示部分論文:

           

          向下滑動查看

           

          [1] Liu R, Yang J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. (IF:55)華東理工大學(xué)生物工程學(xué)院楊弋團(tuán)隊(duì)

          [2] Zhou J, Chen P, et al. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5.(IF:11.454)武漢大學(xué)生命科學(xué)學(xué)院殷雷團(tuán)隊(duì)

          [3] Chen S, Cao X, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Jan 24.(IF:16.808)中國科學(xué)院北京生命科學(xué)研究院趙方慶團(tuán)隊(duì)

          [4] Gu C, Wang Y, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

          [5] Zhang Y, Yu X, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022 Feb.(11.492)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

          [6] Qin J, Cai Y, et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat Commun. 2022 Jan 13.(14.9)四川大學(xué)生物治療國家重點(diǎn)實(shí)驗(yàn)室邵振華團(tuán)隊(duì)

          [7] Tang X, Deng Z, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

          [8] Xie F, Su P, et al. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. Adv Mater. 2021 Oct 19. (IF:30.849)蘇州大學(xué)生物醫(yī)學(xué)研究院周芳芳團(tuán)隊(duì)和浙江大學(xué)生命科學(xué)研究院張龍團(tuán)隊(duì)

          [9] Liang Y, Lu Q, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7.(IF:16.9)復(fù)旦大學(xué)生物醫(yī)學(xué)研究院于文強(qiáng)團(tuán)隊(duì)

          [10] Fan Y, Wang J, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb 2.(IF:27.403)南京醫(yī)科大學(xué)附屬逸夫醫(yī)院蘇東明團(tuán)隊(duì)

          [11] Dai L, Dai Y, et al. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021 Jul 1.(IF:17.97)浙江大學(xué)生命科學(xué)研究院黃俊團(tuán)隊(duì)和中科院生物物理所周政團(tuán)隊(duì)

          [12] Zhang K, Wang A, et al. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron. 2021 Jun 16.(IF:17.17)中國科學(xué)院生物與化學(xué)交叉研究中心王文元團(tuán)隊(duì)

          [13] Li T, Chen X, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021 Jan 27.(IF:14.92)華東理工大學(xué)生物工程學(xué)院楊弋團(tuán)隊(duì)

          [14] Pan Y, He X, et al. Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. Cell Rep. 2021 Jul 20.(IF:9.420)浙江大學(xué)腦科學(xué)與腦醫(yī)學(xué)學(xué)院馬歡團(tuán)隊(duì)

          [15] Liu H, Xing R, et al. G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production. Cell Death Dis. 2021 Jun 12.(IF:8.463)廈門大學(xué)生命科學(xué)學(xué)院陳穎團(tuán)隊(duì)

          [16] Yan F, Huang C, et al. Threonine ADP-Ribosylation of Ubiquitin by a Bacterial Effector Family Blocks Host Ubiquitination. Mol Cell. 2020 May 21.(IF:17.97)浙江大學(xué)生命科學(xué)研究院朱永群團(tuán)隊(duì)

          [17] Luo Q, Wu X, et al. TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Rep. 2020 Jan 7.(IF:9.42)中國醫(yī)學(xué)科學(xué)院分子腫瘤學(xué)國家重點(diǎn)實(shí)驗(yàn)室劉芝華團(tuán)隊(duì)

          [18] Sun X, Peng X, et al. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020 Jun 12.(IF:14.911)中國科學(xué)院水生生物研究所孫玉華團(tuán)隊(duì)

          [19] Yang X, Wang H, et al. Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation. Protein Cell. 2020 Dec.(IF:14.872)浙江大學(xué)醫(yī)學(xué)院/轉(zhuǎn)化醫(yī)學(xué)研究院閔軍霞團(tuán)隊(duì)

          [20] Zou Y, Wang A, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018 Oct.(IF:13.490)華東理工大學(xué)生物工程學(xué)院楊弋、趙玉政團(tuán)隊(duì)

          [21] Zhang K, Zhao X, et al. Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl Mater Interfaces. 2018 Sep 12.(IF:8.09)南開大學(xué)醫(yī)學(xué)院李宗金團(tuán)隊(duì)

          [22] Hao H, Hu S, et al. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017 Mar 28.(IF:29.69)中國醫(yī)學(xué)科學(xué)院/北京協(xié)和醫(yī)學(xué)院阜外醫(yī)院王淼團(tuán)隊(duì)

           

          小翌再給大家展示下Yeasen的轉(zhuǎn)染試劑家族全貌。

          科研路上高分paper發(fā)不停,小翌助您過關(guān)斬將,每天都出好數(shù)據(jù)。

           

          翌圣生物轉(zhuǎn)染試劑產(chǎn)品

           

          應(yīng)用場景

          名稱

          貨號

          規(guī)格

          細(xì)胞類型:貼壁/懸浮

          核酸類型:DNAsiRNA

          Hieff Trans® 脂質(zhì)體核酸轉(zhuǎn)染試劑

          40802ES02

          0.5 mL

          40802ES03

          1.0 mL

          40802ES08

          5×1 mL

          細(xì)胞類型:貼壁/懸浮
          核酸類型:DNA

          磷酸鈣法細(xì)胞轉(zhuǎn)染試劑

          40803ES70

          200 T

          用途:病毒感染、DNA轉(zhuǎn)染

          聚凝胺(10 mg/ml

          40804ES76

          500 μL

          40804ES86

          5×500 μL

          細(xì)胞類型:懸浮
          核酸類型:DNA、siRNA

          Hieff Trans® 懸浮細(xì)胞專用脂質(zhì)體核酸轉(zhuǎn)染試劑

          40805ES02

          0.5 mL

          40805ES03

          1.0 mL

          40805ES08

          5×1 mL

          細(xì)胞類型:貼壁/懸浮
          核酸類型:siRNA、miRNA

          Hieff Trans® siRNA/miRNA體外轉(zhuǎn)染試劑

          40806ES01

          0.1 mL

          40806ES02

          0.5 mL

          40806ES03

          1.0 mL

          細(xì)胞類型:貼壁/懸浮
          核酸類型:DNAsiRNA、miRNA

          Hieff Trans® 通用型轉(zhuǎn)染試劑

          40808ES02

          0.5 mL

          40808ES03

          1 mL

          40808ES08

          5×1 mL

          細(xì)胞類型:貼壁/懸浮
          核酸類型:mRNA

          Hieff Trans® mRNA轉(zhuǎn)染試劑

          40809ES01

          0.1 mL

          40809ES03

          1 mL

          細(xì)胞類型:貼壁/懸浮
          核酸類型:DNA

          PEI轉(zhuǎn)染試劑MW25000

          40815ES03

          1 g

          40815ES08

          5×1 g

          細(xì)胞類型:貼壁/懸浮
          核酸類型:DNA

          線性PEI轉(zhuǎn)染試劑(速溶型)MW40000

          40816ES02

          100 mg

          40816ES03

          1 g

          細(xì)胞類型:293
          核酸類型:DNA
          用途:AAV/LV載體研發(fā)與工藝開發(fā)

          Hieff Trans® PEI轉(zhuǎn)染試劑

          40820ES04

          1.5 mL

          40820ES10

          10 mL

          40820ES60

          100 mL

          細(xì)胞類型:293

          核酸類型:DNA

          用途:AAV/LV載體大規(guī)模生產(chǎn)

          Hieff Trans® PEI Transfection Reagent-GMP

          40821ES10

          10 mL

          40821ES60

          100 mL

          40821ES80

          1 L

          點(diǎn)擊產(chǎn)品名稱查看詳情

           

          福利活動

           
          文末留言分享您的細(xì)胞轉(zhuǎn)染小技巧,留言點(diǎn)贊數(shù)最高的粉絲即可獲得翌圣生物加熱磁力攪拌器一個

          活動時(shí)間:即日起至6月20日24:00

           

          400-6111-883